Cystic Fibrosis (CF) is a genetic disorder caused by mutations in the CF transmembrane conductance regulator (CFTR) protein. This leads to numerous medical problems, including abnormal airway secretions, mucus accumulation, and opportunistic bacterial infections. Pseudomonas aeruginosa is the most significant pathogen, with > 80% of CF patients becoming chronically infected with P. aeruginosa by 18 years of age. Extensive antibiotic treatment has led to selection of resistant strains, which are less responsive to drug treatments and exacerbate disease progression.
Despite antibiotic treatment, almost all CF patients ultimately succumb to respiratory failure due to chronic P. aeruginosa infection and airway inflammation.
Aridis’ AR-501 (Panaecin™) is a promising inhalable broad-spectrum anti-infective currently under development for controlling these debilitating chronic lung infections in CF patients.